Table 4 Comorbidities of patients hospitalized who underwent a bioprosthetic mitral valve replacement in Spain from 2001 to 2015 according to type 2 diabetes status
T2DM | 2001–2005 | 2006–2010 | 2011–2015 | Total | Trend | |
|---|---|---|---|---|---|---|
Mitral stenosis, n (%) | Yes | 15 (6.85) | 23 (5.12) | 37 (5.9) | 75 (5.79) | 0.660 |
No | 67 (5.91) | 96 (5.06) | 109 (4.03) | 272 (4.74) | 0.032 | |
Rheumatic mitral insufficiency, n (%) | Yes | 8 (3.65) | 12 (2.67) | 20 (3.19) | 40 (3.09) | 0.773 |
No | 28 (2.47) | 87 (4.58) | 82 (3.03) | 197 (3.43) | 0.002 | |
Mitral stenosis with insufficiency, n (%) | Yes | 25 (11.42) | 55 (12.25) | 58 (9.25) | 138 (10.66) | 0.268 |
No | 109 (9.61) | 187 (9.85) | 238 (8.8) | 534 (9.31) | 0.442 | |
Charlson Comorbidity Index, mean (SD) | Yes | 1.05 (0.88) | 0.96 (0.79) | 1.12 (0.85) | 1.05 (0.83) | 0.167 |
No | 0.87 (0.78) | 0.98 (0.8) | 1.06 (0.86) | 0.99 (0.83) | < 0.001 | |
Chronic obstructive pulmonary disease, n (%) | Yes | 27 (12.33) | 40 (8.91) | 52 (8.29) | 119 (9.19) | 0.199 |
No | 81 (7.14) | 130 (6.85) | 218 (8.06) | 429 (7.48) | 0.276 | |
Peripheral vascular disease, n (%) | Yes | 7 (3.2) | 16 (3.56) | 32 (5.1) | 55 (4.25) | 0.326 |
No | 43 (3.79) | 101 (5.32) | 142 (5.25) | 286 (4.98) | 0.119 | |
Acute renal disease, n (%) | Yes | 31 (14.16) | 80 (17.82) | 128 (20.41) | 239 (18.46) | 0.110 |
No | 145 (12.79) | 318 (16.75) | 575 (21.25) | 1038 (18.09) | < 0.001 | |
Cerebrovascular disease, n (%) | Yes | 11 (5.02) | 19 (4.23) | 33 (5.26) | 63 (4.86) | 0.735 |
No | 47 (4.14) | 102 (5.37) | 155 (5.73) | 304 (5.3) | 0.134 | |
Congestive heart failure, n (%) | Yes | 64 (29.22) | 114 (25.39) | 185 (29.51) | 363 (28.03) | 0.304 |
No | 287 (25.31) | 519 (27.34) | 818 (30.23) | 1624 (28.3) | 0.004 | |
Atrial fibrillation, n (%) | Yes | 113 (51.6) | 253 (56.35) | 377 (60.13) | 743 (57.37) | 0.077 |
No | 562 (49.56) | 1078 (56.8) | 1587 (58.65) | 3227 (56.24) | < 0.001 | |
Pulmonary hypertension, n (%) | Yes | 66 (30.14) | 133 (29.62) | 195 (31.1) | 394 (30.42) | 0.869 |
No | 271 (23.9) | 564 (29.72) | 791 (29.23) | 1626 (28.34) | 0.001 | |
Coronary artery disease, n (%)* | Yes | 87 (39.73) | 165 (36.75) | 229 (36.52) | 481 (37.14) | 0.684 |
No | 297 (26.19) | 508 (26.77) | 727 (26.87) | 1532 (26.7) | 0.908 | |
Obesity, n (%)* | Yes | 26 (11.87) | 43 (9.58) | 87 (13.88) | 156 (12.05) | 0.102 |
No | 39 (3.44) | 85 (4.48) | 162 (5.99) | 286 (4.98) | 0.002 | |
Cardiogenic shock, n (%) | Yes | 11 (5.02) | 22 (4.9) | 23 (3.67) | 56 (4.32) | 0.530 |
No | 67 (5.91) | 106 (5.58) | 144 (5.32) | 317 (5.52) | 0.761 | |
Endocarditis, n (%) | Yes | 32 (14.61) | 74 (16.48) | 123 (19.62) | 229 (17.68) | 0.176 |
No | 154 (13.58) | 337 (17.76) | 618 (22.84) | 1109 (19.33) | < 0.001 | |
Pneumonia, n (%) | Yes | 6 (2.74) | 17 (3.79) | 15 (2.39) | 38 (2.93) | 0.403 |
No | 59 (5.2) | 63 (3.32) | 104 (3.84) | 226 (3.94) | 0.034 | |
Renal disease, n (%)* | Yes | 20 (9.13) | 45 (10.02) | 99 (15.79) | 164 (12.66) | 0.004 |
No | 73 (6.44) | 153 (8.06) | 305 (11.27) | 531 (9.25) | < 0.001 | |
Liver disease, n (%) | Yes | 7 (3.2) | 12 (2.67) | 27 (4.31) | 46 (3.55) | 0.344 |
No | 39 (3.44) | 65 (3.42) | 119 (4.4) | 223 (3.89) | 0.167 | |
Cancer, n (%) | Yes | 4 (1.83) | 6 (1.34) | 4 (0.64) | 14 (1.08) | 0.278 |
No | 10 (0.88) | 27 (1.42) | 38 (1.4) | 75 (1.31) | 0.371 | |
Weight loss, n (%) | Yes | 0 (0) | 1 (0.22) | 4 (0.64) | 5 (0.39) | 0.334 |
No | 3 (0.26) | 7 (0.37) | 11 (0.41) | 21 (0.37) | 0.802 |